Avidity Biosciences
RNA Micro CapHealthcare · Biotechnology
Mis à jour: Jun 18, 2026, 22:21 UTC
Price Chart
Indicateurs clés
Valuation Analysis
About the Company
Avidity Biosciences en bref
Avidity Biosciences (RNA) is currently trading at 11,05 € with a market capitalization of 189 M €. The 52-week range spans from 9,95 € to 14,63 €; the current price is 24.5% below the yearly high. Year-over-year revenue growth stands at +1148.3%.
💰 Dividende
Avidity Biosciences currently does not pay a dividend. The company typically reinvests its earnings into growth initiatives and product development.
📊 Avis des analystes
2 analystes évaluent Avidity Biosciences (RNA) au consensus : None. L'objectif de cours moyen est de 21,82 €, soit un potentiel de +97.47% par rapport au cours actuel. La fourchette des objectifs de cours des analystes va de 21,82 € à 21,82 €.
Avidity Biosciences : la thèse d'investissement en détail
Avidity Biosciences (RNA) operates in the Healthcare — specifically Biotechnology — and is headquartered in United States. Below is a structured read of the investment case built directly from the latest fundamentals, valuation multiples, analyst positioning and smart-money flows. Each section translates raw numbers into the investment logic they imply, so you can decide whether the risk/reward fits your portfolio.
Le scénario haussier
Top-line momentum is unusually strong with revenue expanding 1148.3% year-over-year, a pace that puts the company well above the market average and signals genuine demand traction rather than mere cyclical tailwind.
Le scénario baissier
Net margins remain negative, meaning every euro of revenue is still producing losses — the path to profitability is the central question for shareholders.
Valorisation en contexte
The EV/EBITDA multiple of 0.84x is below the historical equity-market average — strategic acquirers would find the cash-flow profile attractive at this level.
À surveiller
- The price sits in the lower quartile of the 52-week range — value hunters often start scaling in around this zone if fundamentals hold.
- The analyst consensus price target implies 97.47% upside — if the next two quarters confirm the underlying thesis, target hikes typically follow.
Thèse d'investissement : forces et faiblesses
- Forte croissance du CA de 1148.3% sur un an
- Bilan solide avec faible endettement (D/E 1.15)
- –Actuellement non rentable
Aperçu technique
Price is below both the 50- and 200-day moving averages, with 50d below 200d — a bearish picture (death-cross alignment).
Profil de risque
Trading Data
Related Stocks in the Same Sector
More Santé stocks
Top peers in the same sector — ranked by market cap.
Where can I buy Avidity Biosciences?
Compare top-rated brokers — low fees, trusted providers, fully regulated.
Live Market Data
Real-time chart, financials, earnings, analysts, insider trades, events & news